Association Of Initial Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment And EGFR Exon 19 Deletion With Frequency Of The T790M Mutation In Non-Small Cell Lung Cancer Patients After Resistance To First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Wen Gao,Jing He,Shi-Dai Jin,Jing Xu,Tong-Fu Yu,Wei Wang,Quan Zhu,Hui Dai,Hao Wu,Yi-Qian Liu,Yong-Qian Shu,Ren-Hua Guo
DOI: https://doi.org/10.2147/OTT.S220383
IF: 4
2019-11-09
OncoTargets and Therapy
Abstract:Wen Gao, 1, * Jing He, 1, * Shi-Dai Jin, 1, * Jing Xu, 1 Tong-Fu Yu, 2 Wei Wang, 3 Quan Zhu, 2 Hui Dai, 4 Hao Wu, 1 Yi-Qian Liu, 1 Yong-Qian Shu, 1 Ren-Hua Guo 1 1 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People's Republic of China; 2 Department of Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People's Republic of China; 3 Department of Thoracic Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People's Republic of China; 4 Medical Records Statistics, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People's Republic of China *These authors contributed equally to this work Correspondence: Ren-Hua Guo; Yong-Qian Shu Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, People's Republic of China Email rhguo@njmu.edu.cn; shuyongqian@csco.org.cn Background: The present study analyzed the relationship between clinical features and the T790M mutation in non-small cell lung cancer (NSCLC) patients resistant to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment. Methods: NSCLC patients with resistance to first-generation EGFR-TKIs in which the disease control time was more than 6 months after initial TKI treatment were enrolled. T790M mutation analysis was performed using one of the following methods according to each manufacturer's protocols: Cobas EGFR mutation test (41/105, 39.0%), digital PCR (42/105, 40.0%) or Scorpion amplification refractory mutation system (ARMS) (22/105, 21.0%). Sample type of T790M was from tissue only (53/105, 50.5%), plasma only (46/105, 43.8%), tissue and plasma (6/105, 5.7%). Results: Of 105 patients, 57 were T790M-positive and 48 were T790M-negative. T790M-positive patients had longer progression-free survival (PFS) after initial EGFR-TKI treatment (p = 0.019). T790M positivity was more frequent in patients treated with gefitinib than in those treated with icotinib (65% vs 40.54%, p = 0.018). The rate of T790M positivity was lower in patients with EGFR L858R (44.44%, 12/27) before TKI treatment than in those with EGFR 19del (72.0%, 36/50, p = 0.036). Patients who achieved PR after initial EGFR-TKI treatment had a higher rate of T790M positivity than those with SD (75.76% vs 50%, p = 0.023). There was no relationship between T790M status and age, gender, primary site, metastasis site, or treatment before TKI. Conclusion: Progression-free survival (PFS), drug type, response to initial EGFR-TKI treatment, and EGFR status before initial EGFR treatment were associated with the frequency of T790M mutation. Keywords: lung cancer, EGFR, T790M, gefitinib, icotinib
oncology,biotechnology & applied microbiology